Guidelines (KDIGO) advise the use of GLP1 receptor agonists in patients with T2DM and CKD who have not achieved glycemic targets with metformin and SGLT2 inhibitors [63]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.